DURHAM, N.C. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that management will present at two upcoming investor conferences in November.
DURHAM, N.C. , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of innovative medicines to treat patients with cancer and other serious diseases, today announced that it will host a live conference call and audio
Includes All Human Indications Excluding Prevention and Treatment of Smallpox Chimerix to Receive up to $180 Million in Potential Clinical, Regulatory, and Commercial Milestones and is Eligible for Double Digit Royalties DURHAM, N.C. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a
DURHAM, N.C. , Sept. 27, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX) today announced that Mike Sherman , Chief Executive Officer, will present a corporate overview at the upcoming 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 8:20 a.m. ET in New York City.
Pipeline Transformed with Acquisition of Global Rights to Late Stage Oncology Asset (CX-01) with Fast Track and Orphan Drug Designation Phase 3 Trial of CX-01 in Front-Line Acute Myeloid Leukemia Planned to Initiate in Mid 2020 Finalizing Animal Studies of Brincidofovir as Smallpox Medical
Transformational Transaction Provides Key Program in First-Line Acute Myeloid Leukemia with Fast Track and Orphan Drug Designations and Potential Utility as a Platform Technology Phase II Randomized Data Presented at ASCO 2019 Demonstrated Compelling Complete Response Rates,
– Reports Positive Top-line Survival Data from Pivotal Mouse Study as Key Milestone on Path to Smallpox Regulatory Submission – – Plan to Focus on Execution of Smallpox Program, Halting All Other Brincidofovir Development Activities – – Restructuring to Reduce Workforce by More Than 50%,
DURHAM, N.C. , May 02, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced that it will host a live conference call and audio webcast on Thursday, May 9, 2019 at 8:30 a.m.
Mike Sherman Appointed Chief Executive Officer and Mike Andriole Appointed Chief Business Officer DURHAM, N.C. , April 08, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announces the appointment of
– Reports Positive Preliminary Top-line Data from Second Rabbitpox Study – – Type C Meeting Requested with FDA Regarding Virologic Endpoint – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C. , March 05, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing
